Nonalcoholic Steatohepatitis: Epidemiology, Screening, Risk Assessment, Diagnosis, and Management

  • Author: Philip N. Newsome, PhD, FRCPE (More Info)
  • Editor In Chief: Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
  • Last Reviewed: 8/23/19 (What's New)

Summary

  • Both liver and overall health benefit from management of common comorbidities such as dyslipidemia, hypertension, and T2DM
    • The initiation of lipid-lowering pharmacotherapy depends on the patient’s lipid profile and risk factors for atherosclerotic cardiovascular disease[Grundy 2019]
      • Guidance on initiation of moderate-intensity to high-intensity statin therapy is available from the 2018 American College of Cardiology/American Heart Association Task Force guidelines on managing blood cholesterol

Action required